Altimmune (ALT)
(Delayed Data from NSDQ)
$6.43 USD
+0.13 (2.06%)
Updated Oct 14, 2024 04:00 PM ET
After-Market: $6.44 +0.01 (0.16%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth D Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$6.43 USD
+0.13 (2.06%)
Updated Oct 14, 2024 04:00 PM ET
After-Market: $6.44 +0.01 (0.16%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth D Momentum F VGM
Zacks News
Altimmune (ALT) Begins Phase II Study for Chronic Hepatitis B
by Zacks Equity Research
Altimmune (ALT) enrolls the first patient in a phase II study evaluating HepTcell for the treatment of patients with chronic hepatitis B. Shares rise.
Altimmune (ALT) Files IND for Phase I Study on Coronavirus Vaccine
by Zacks Equity Research
Altimmune (ALT) files a regulatory application to begin a phase I study in the United States on AdCOVID, its intranasal COVID-19 vaccine candidate. Stock rises.
Company News for Jul 13, 2020
by Zacks Equity Research
Companies in the news are: BNGO, AMRX, ALT, EXPR
Are Options Traders Betting on a Big Move in Altimmune (ALT) Stock?
by Zacks Equity Research
Investors need to pay close attention to Altimmune (ALT) stock based on the movements in the options market lately.
Is the Options Market Predicting a Spike in Altimmune (ALT) Stock?
by Zacks Equity Research
Investors need to pay close attention to Altimmune (ALT) stock based on the movements in the options market lately.
Company News for Mar 2, 2020
by Zacks Equity Research
Companies in the news are: ALT, BIG, W, CDXS
Will Altimmune (ALT) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Altimmune (ALT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.